意大利2021/2022流感疫苗接种运动安全性:自控病例系列研究
本研究利用意大利多地区健康数据,采用自控病例系列设计评估2021/2022流感疫苗接种后预先设定的潜在不良结局。结果显示大多数结局风险未增加,但60岁以下人群接种后42天内血小板减少症和视神经炎风险升高,需进一步研究。
要点
- 流感疫苗总体安全性良好,多数预设不良结局风险未增加。
- 60岁以下人群接种后42天内血小板减少症风险升高(RI=1.90)。
- 视神经炎风险亦升高(RI=5.22),但置信区间宽,需进一步验证。
核心结论
- 流感疫苗在2021/2022接种运动中总体安全,多数预设不良结局无风险增加证据。
- 观察到血小板减少症和视神经炎风险增加,需进一步研究。
研究设计与样本
- 多地区研究,使用区域健康数据登记评估2021/2022流感疫苗接种后预设不良结局。
- 采用修改的自控病例系列设计(SCCS),参与者为6月龄及以上因兴趣结局就诊急诊或住院者。
- 针对每个结局定义风险期并与参照期比较,估计相对发病率和超额病例,按年龄、性别、剂次分层并调整日历时间。
主要发现
- 大多数研究结局未观察到风险增加。
- 60岁以下人群接种后42天内血小板减少症风险增加(RI=1.90;95%CI:1.00-3.61)。
- 60岁以下人群接种后42天内视神经炎风险增加(RI=5.22;95%CI:1.31-20.79)。
- 敏感性和辅助分析支持上述发现。
临床怎么用
- 流感疫苗接种总体安全,可继续推荐接种。
- 对60岁以下接种者,关注血小板减少症和视神经炎相关症状,但当前证据不足以改变接种策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This study evaluated the safety of influenza vaccines in a large and representative population during the 2021/2022 campaign in Italy using a Self-Controlled Case Series (SCCS) design using regional health data registries. METHODS: This multiregional study used healthcare data to assess pre-specified potential adverse outcomes after flu vaccination during the 2021/2022 season. Participants were individuals aged 6 months or older, vaccinated or not, admitted to emergency care or hospital for at least one of the incident outcomes of interest. Risk periods were specifically defined for each outcome and compared to reference periods. The Self-Controlled Case Series design modified for event-dependent exposures was used, estimating relative incidences and excess cases by age, sex, dose, and adjusting for calendar time. RESULTS: No increased risks were observed for most of the study outcomes. An increased risk of thrombocytopenia (RI = 1.90; 95% CI: 1.00-3.61) and optic nerve neuritis (RI = 5.22; 95% CI: 1.31-20.79) was detected within 42 days after vaccination in individuals under 60 years. Sensitivity and ancillary analyses supported these findings. CONCLUSIONS: These findings confirm the overall safety of influenza vaccines during the 2021/2022 campaign, with no evidence of increased risk for most of the pre-specified adverse outcomes. The increased risks observed for thrombocytopenia and optic neuritis need further research.
引用
- Spila-Alegiani S, Massari M, Cutillo M, et al. Safety of influenza vaccine during the vaccination campaign 2021/2022 in Italy: a self-controlled case series study. Vaccine. 2026. PMID: 42284809. doi:10.1016/j.vaccine.2026.128806
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。